Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial

অনুরূপ উপাদানগুলি

• Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin
  অনুযায়ী: Shah, Viral N., অন্যান্য
  প্রকাশিত: (2021)
• Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial
  অনুযায়ী: Garg, Satish K., অন্যান্য
  প্রকাশিত: (2020)
• A single‐dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US‐ and European‐approved versions of insulin aspart Mix 70/30 and SAR341402 rapid‐acting solution in subjects with type 1 diabetes
  অনুযায়ী: Kapitza, Christoph, অন্যান্য
  প্রকাশিত: (2020)
• Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)
  অনুযায়ী: Garg, Satish K., অন্যান্য
  প্রকাশিত: (2020)
• Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
  অনুযায়ী: Thrasher, James, অন্যান্য
  প্রকাশিত: (2018)